{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Aapro MS"],"funding":["No medical writer company or paid editorial support was needed.","This RFP was supported by Pfizer Inc. This work was supported by Pfizer Inc. The funder had no role in the design of the studies; in the collection, analyses, or interpretation of data; or in the decision to publish the results."],"pagination":["547"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12563530"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(10)"],"pubmed_abstract":["Breast cancer (BC) is the most frequently diagnosed malignancy in women. Currently, BC is treated with a holistic and multidisciplinary approach from diagnostic, surgical, radio-oncological, and medical perspectives, and advances including in early detection and treatment methods have led to improved outcomes for patients in recent years. Yet, BC remains the second most common cause of cancer-related deaths among women and there is an array of gaps to achieve optimal care. To close gaps in cancer care, here we describe a collaborative Request For Proposals (RFP) framework supporting independent initiatives for metastatic breast cancer (MBC) patients and aiming at improving their quality of care. We set up a collaborative framework between Pfizer and Sharing Progress in Cancer Care (SPCC). "],"journal":["Current oncology (Toronto, Ont.)"],"pubmed_title":["Collaborative Funding Model to Improve Quality of Care for Metastatic Breast Cancer in Europe."],"pmcid":["PMC12563530"],"funding_grant_id":["N.A."],"pubmed_authors":["Masiero M","Matuszewska J","Wuerstlein R","Henze F","Pravettoni G","Waldrop J","Paluch-Shimon S","Fenderico N","Zambon M","Aapro MS","Drury A","Wiseman T","Simon Robleda S","Ciani O","Presti P"],"additional_accession":[]},"is_claimable":false,"name":"Collaborative Funding Model to Improve Quality of Care for Metastatic Breast Cancer in Europe.","description":"Breast cancer (BC) is the most frequently diagnosed malignancy in women. Currently, BC is treated with a holistic and multidisciplinary approach from diagnostic, surgical, radio-oncological, and medical perspectives, and advances including in early detection and treatment methods have led to improved outcomes for patients in recent years. Yet, BC remains the second most common cause of cancer-related deaths among women and there is an array of gaps to achieve optimal care. To close gaps in cancer care, here we describe a collaborative Request For Proposals (RFP) framework supporting independent initiatives for metastatic breast cancer (MBC) patients and aiming at improving their quality of care. We set up a collaborative framework between Pfizer and Sharing Progress in Cancer Care (SPCC). ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-05-14T03:17:06.626Z","creation":"2026-05-14T03:11:56.764Z"},"accession":"S-EPMC12563530","cross_references":{"pubmed":["41149467"],"doi":["10.3390/curroncol32100547"]}}